Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Description
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
